SLC16A3 and hepatocellular carcinoma: We established a subcutaneous tumour model of mouse hepatocellular carcinoma (HCC) and utilised an SLC16A3 inhibitor (MCT4i) to investigate the role of SLC16A3 in HCC progression (Figure 8A).